Skip to main content
ASHI 50th Annual Meeting Mobile App Main banner
Back

Mark Yarmarkovich, PhD

NYU School of Medicine

Dr. Mark Yarmarkovich is focused on developing the next generation of cancer immunotherapies to unleash the potent potential of these therapies for all cancer patients. Leveraging his multidisciplinary expertise in protein science, antibody engineering, immunology and computational biology, he has led the discovery of novel tumor antigens and pioneered a new class of peptide-centric (PC)-CAR T cells. These PC-CARs enable the targeting of non-immunogenic tumor antigens presented on MHC across multiple HLA allotypes. The first PC-CARs potently eradicate aggressive tumors in preclinical models and are entering clinical trials in 2024/5. Dr. Yarmarkovich completed his PhD at the University of Pennsylvania, his postdoc at the Children’s Hospital of Philadelphia and has worked for 5 years at Genentech. He is the inventor on 10 patents related to cancer immunotherapy and has founded two companies focused translating immunotherapies to patients.

Disclosure information not submitted.

Presentation(s):